Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Search trials by disease or condition

Enter a condition, keyword, or NCT ID

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “multiple sclerosis”

Copaxone Subcutaneous Injection Syringe Special Drug Use-Result Investigation (All-Case Investigation) "Prevention of Relapse of Multiple Sclerosis"Completed
NCT03209479N/AUpdated Jun 13, 2024
Sponsor: Teva Takeda Pharma Ltd.
Multiple Sclerosis
Japan
A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab AdministrationCompleted
NCT03689972Phase 3Updated Jun 12, 2024
Sponsor: Biogen
Multiple Sclerosis, Relapsing-Remitting
United States, Australia, Belgium, Canada, France +6 more
Effect of Adding Modified Ketogenic Diet to Exercise Program in Treating Obese Patient With Multiple Sclerosis: A Randomized Controlled TrialUnknown
NCT06454162NAUpdated Jun 12, 2024
Sponsor: Cairo University
Multiple Sclerosis
Low-Load Blood Flow Restriction on Patients With Multiple SclerosisCompleted
NCT05177952NAUpdated Jun 11, 2024
Sponsor: University of Central Florida
Training Study · Multiple Sclerosis · Blood Flow Restriction
United States
An Observational Biomarker Study in Multiple Sclerosis (MS) PatientsCompleted
NCT05663853N/AUpdated Jun 11, 2024
Sponsor: LAPIX Therapeutics Inc.
Multiple Sclerosis, Relapsing-Remitting · Multiple Sclerosis, Primary Progressive · Multiple Sclerosis, Secondary Progressive
United States
Enhancing Quality of Life in MS Patients Through Tailored Therapeutic EducationUnknown
NCT06450600NAUpdated Jun 10, 2024
Sponsor: Akhrif Iman
Multiple Sclerosis (MS)
Trunk Rehabilitation Compared to Core Stability in Patients With Multiple SclerosisUnknown
NCT06447571NAUpdated Jun 7, 2024
Sponsor: King Abdulaziz University
Multiple Sclerosis · Trunk · Physical Therapy
Saudi Arabia
Next-Gen MS: Feed-forward PRO Data for MS ResearchTerminated
NCT04907305N/AUpdated Jun 6, 2024
Sponsor: EMD Serono Research & Development Institute, Inc.
Multiple Sclerosis (MS)
United States
National, Multicentric Registry Study on Neuroimmunological Diseases in ChinaUnknown
NCT06443333N/AUpdated Jun 5, 2024
Sponsor: Xuanwu Hospital, Beijing
Multiple Sclerosis · NMO Spectrum Disorder · Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease · Myasthenia Gravis
China
High-Intensity, Dynamic-stability Gait Training in People With Multiple SclerosisRecruiting
NCT05735691NAUpdated Jun 5, 2024
Sponsor: Marquette University
Multiple Sclerosis
United States
Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)Completed
NCT01665144Phase 3Updated Jun 5, 2024
Sponsor: Novartis Pharmaceuticals
Secondary Progressive Multiple Sclerosis
United States, Argentina, Australia, Austria, Belgium +26 more
Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS)Completed
NCT02688985Phase 3Updated Jun 4, 2024
Sponsor: Genentech, Inc.
Relapsing Multiple Sclerorsis · Multiple Sclerosis, Primary Progressive
United States, Canada, Germany, Sweden
Productive Value of Sonographic Measurement of Optic Nerve in Transitional MultipleUnknown
NCT06435962N/AUpdated Jun 4, 2024
Sponsor: Assiut University
Relapsing Remitting Multiple Sclerosis
potentiALS - Quality of Life Among Patients With Amyotrophic Lateral SclerosisUnknown
NCT06441448N/AUpdated Jun 4, 2024
Sponsor: University of Leipzig
Amyotrophic Lateral Sclerosis
Germany
Natalizumab Subcutaneous Immunogenicity and Safety StudyTerminated
NCT02142192Phase 2Updated Jun 3, 2024
Sponsor: Biogen
Relapsing Multiple Sclerosis
Belgium
Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)Active Not Recruiting
NCT05103358Phase 2Updated Jun 3, 2024
Sponsor: Aadi Bioscience, Inc.
Tumor · Tumor, Solid · Metastasis · Metastatic Cancer
United States, Puerto Rico, South Korea
Canadian Multicenter Observational Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis ParticipantsTerminated
NCT01706107N/AUpdated Jun 3, 2024
Sponsor: Biogen
Relapsing-Remitting Multiple Sclerosis
Canada
A Proof-of-Concept Study to Correlate Retinal Nerve Fiber Layer Changes in Patients With Multiple Sclerosis Treated With Natalizumab or Interferon Beta 1-aWithdrawn
NCT00771043Phase 4Updated Jun 3, 2024
Sponsor: Biogen
Relapsing-remitting Multiple Sclerosis
Mechanistic Study of OcrevusCompleted
NCT04459988N/AUpdated May 31, 2024
Sponsor: University of Michigan
Multiple Sclerosis
United States
Cognition and HRQoL in Adults With Highly-active RMS in Year 3 and 4 After Initial Mavenclad® Dose (CLARIFY MS Extension)Completed
NCT04776213Phase 4Updated May 28, 2024
Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Multiple Sclerosis
Austria, Czechia, Denmark, France, Hungary +5 more
The Efficacy of Tele Rehabilitation- Based Task-Specific Training for Cognitive Function ImprovementUnknown
NCT06428201NAUpdated May 24, 2024
Sponsor: Superior University
Sclerosis, Multiple
Pakistan
Rex Robot Assisted Rehabilitation to Enhance Balance and Mobility for People With Multiple Sclerosis, Clinical and Biomarker Study - RAPPER IVCompleted
NCT06429085Phase 1Updated May 24, 2024
Sponsor: East Kent Hospitals University NHS Foundation Trust
Multiple Sclerosis
United Kingdom
Prebiotic vs Probiotic in Multiple SclerosisCompleted
NCT04038541NAUpdated May 22, 2024
Sponsor: Columbia University
Multiple Sclerosis · Clinically Isolated Syndrome (CIS)
United States
A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple SclerosisRecruiting
NCT05906992Phase 3Updated May 22, 2024
Sponsor: Celltrion
Relapsing-remitting Multiple Sclerosis
Poland
Serial Collection of Primary Progressive Multiple Sclerosis Participants in the MURDOCK StudyCompleted
NCT01776060N/AUpdated May 21, 2024
Sponsor: Duke University
Primary Progressive Multiple Sclerosis
United States

Previous page Next page